C34 C46 C56 C50
Conditions
Interventions
Group 1: The study will document the treatment of patients with ovarian carcinoma, patients with breast carcinoma, patients with advanced non-small cell lung cancer and patients with AIDS-associated K
Sponsors
AxioNovo Gmbh
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Patients with non-small cell lung cancer for whom first-line therapy with axitaxel® is indicated (as monotherapy or combination therapy). - Patients with breast or ovarian cancer for whom first-line or second-line therapy with axitaxel® is indicated (as monotherapy or combination therapy). - Patients with AIDS-associated Kaposi's sarcoma in whom therapy with axitaxel® is indicated in accordance with the specialist information (as monotherapy or combination therapy).
Exclusion criteria
Exclusion criteria: - Contraindications to use in the axitaxel® SmPC. - Lack of patient consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Progression during therapy by clinical examination, imaging, or special laboratory at the end of each cycle and at unscheduled visits | — |
Secondary
| Measure | Time frame |
|---|---|
| - Diarrhea or neutropenia Toxicity grade 4 during the course of therapy as assessed by clinical examination or laboratory at the end of each cycle and at unscheduled visits. - Poor tolerability in general surveyed at the end of each cycle and at unscheduled visits. | — |
Countries
Germany
Contacts
Public ContactBurkard Heckelbacher
Datafaber GbR
Outcome results
None listed